319 related articles for article (PubMed ID: 36588414)
1. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
Dinc R
Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
[TBL] [Abstract][Full Text] [Related]
2. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
Srivastava S; Shankar P; Mishra J; Singh S
Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
[TBL] [Abstract][Full Text] [Related]
3. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
4. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
[TBL] [Abstract][Full Text] [Related]
5. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
6. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
7. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
Pandey SC; Kumar A; Samant M
Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
[TBL] [Abstract][Full Text] [Related]
8. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
9. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
10. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.
Selvapandiyan A; Dey R; Nylen S; Duncan R; Sacks D; Nakhasi HL
J Immunol; 2009 Aug; 183(3):1813-20. PubMed ID: 19592661
[TBL] [Abstract][Full Text] [Related]
11. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
12. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
13. Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
Lage DP; Machado AS; Freitas CS; Vale DL; Linhares FP; Cardoso JMO; Oliveira-da-Silva JA; Ramos FF; Pereira IAG; Ludolf F; Tavares GSV; Bandeira RS; Oliveira JS; Menezes-Souza D; Duarte MC; Galdino AS; Christodoulides M; Chávez-Fumagalli MA; Roatt BM; Martins VT; Coelho EAF
Mol Immunol; 2023 Mar; 155():79-90. PubMed ID: 36731193
[TBL] [Abstract][Full Text] [Related]
14. Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.
Coutinho De Oliveira B; Duthie MS; Alves Pereira VR
Hum Vaccin Immunother; 2020 Apr; 16(4):919-930. PubMed ID: 31634036
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
Kumar A; Samant M
Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
[TBL] [Abstract][Full Text] [Related]
16. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
17. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
Pirdel L; Farajnia S
Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
[TBL] [Abstract][Full Text] [Related]
18. Peptide Vaccines for Leishmaniasis.
De Brito RCF; Cardoso JMO; Reis LES; Vieira JF; Mathias FAS; Roatt BM; Aguiar-Soares RDDO; Ruiz JC; Resende DM; Reis AB
Front Immunol; 2018; 9():1043. PubMed ID: 29868006
[TBL] [Abstract][Full Text] [Related]
19. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
20. Vaccination against cutaneous leishmaniasis: current status.
Melby PC
Am J Clin Dermatol; 2002; 3(8):557-70. PubMed ID: 12358557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
